Should our successor Committee wish to consider the antimicrobial potential of bacteriophages, we recommend: • Seeking updates on whether the MHRA has produced guidance relating to the data that would be required to evaluate applications for clinical trials and licensed phage products promised in the Government’s response; • Asking for updates on what progress the MHRA is making on producing a future ‘monograph’ - directive guidance for medical clinicians - for the compassionate use of phages; • Regularly tracking the latest phage developments from Innovate UK’s Phage Knowledge Transfer Network, which is bringing about collaboration between phage researchers, companies, research funders and regulators; • Scrutinising whether opportunities for phage research funding, phage infrastructure, including Good Manufacturing Practice (GMP) facilities, and access to specialist laboratories, such as those run by UKHSA, have improved; and • Questioning whether lessons are being learnt from phages that can be applied to similar personalised therapeutics that are not produced to a single formulation.